Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Non-Current Deffered Revenue (2023 - 2025)

Historic Non-Current Deffered Revenue for BridgeBio Pharma (BBIO) over the last 3 years, with Q3 2025 value amounting to $13.1 million.

  • BridgeBio Pharma's Non-Current Deffered Revenue fell 2950.56% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 2950.56%. This contributed to the annual value of $17.1 million for FY2024, which is 35867.99% up from last year.
  • Per BridgeBio Pharma's latest filing, its Non-Current Deffered Revenue stood at $13.1 million for Q3 2025, which was down 2950.56% from $14.7 million recorded in Q2 2025.
  • BridgeBio Pharma's Non-Current Deffered Revenue's 5-year high stood at $19.9 million during Q1 2024, with a 5-year trough of $3.7 million in Q4 2023.
  • Over the past 3 years, BridgeBio Pharma's median Non-Current Deffered Revenue value was $17.0 million (recorded in 2024), while the average stood at $15.2 million.
  • As far as peak fluctuations go, BridgeBio Pharma's Non-Current Deffered Revenue surged by 35867.99% in 2024, and later tumbled by 2950.56% in 2025.
  • Quarter analysis of 3 years shows BridgeBio Pharma's Non-Current Deffered Revenue stood at $3.7 million in 2023, then soared by 358.68% to $17.1 million in 2024, then dropped by 23.19% to $13.1 million in 2025.
  • Its last three reported values are $13.1 million in Q3 2025, $14.7 million for Q2 2025, and $17.5 million during Q1 2025.